Early-onset Crohn's disease is a risk factor for smaller final height. by Herzog, Denise et al.
Early-onset Crohn’s disease is a risk factor for smaller
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Objectives Growth retardation is a frequent complication
of paediatric inflammatory bowel disease (IBD). Only a few
studies report the final height of these patients, with
controversial results. We compared adult height of patients
with paediatric IBD with that of patients with adult-onset
disease.
Methods Height data of 675 women 19–44 years of age
and 454 men 23–44 years of age obtained at inclusion in the
Swiss IBD cohort study registry were grouped according to
the age at diagnosis: (a) prepubertal (men≤ 13,
women≤ 11 years), (b) pubertal (men 13–22, women
11–18 years) and (c) adult (men> 22, women> 18 years of
age), and compared with each other and with healthy
controls.
Results Male patients with prepubertal onset of Crohn’s
disease (CD) had significantly lower final height (mean
172±6 cm, range 161–182) compared with men with
pubertal (179±6 cm, 161–192) or adult (178±7 cm,
162–200) age at onset and the general population
(178±7 cm, 142–204). Height z-scores standardized
against heights of the normal population were significantly
lower in all patients with a prepubertal diagnosis of CD
(− 0.8± 0.9) compared with the other patient groups
(− 0.1± 0.8, P< 0.001). Prepubertal onset of CD emerged as
a risk factor for reduced final height in patients with
prepubertal CD. No difference for final height was found
between patients with ulcerative or unclassified IBD
diagnosed at prepubertal, pubertal or adult age.
Conclusion Prepubertal onset of CD is a risk for lower final
height, independent of the initial disease location and the
necessity for surgical interventions. Eur J Gastroenterol
Hepatol 26:1234–1239 © 2014 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
Growth retardation is a frequent extra-intestinal mani-
festation of paediatric onset inflammatory bowel disease
(IBD) [1]. Its prevalence ranges from 13 and 58%,
although much higher values have also been reported.
Growth retardation is more commonly encountered in
Crohn’s disease (CD) than in ulcerative colitis (UC) [2],
and most importantly, in patients with disease onset
before or during early stages of puberty [3–5]. In contrast,
most patients with a later diagnosis achieve normal adult
height [6]. However, it remains unclear whether the
growth deceleration at disease onset is temporary and
compensated by a catch-up growth or whether it results
in a reduced final height. Only a few reports have
documented final adult height [4–9]. Most of these stu-
dies have been carried out in paediatric populations and
define adult height as having completed 18 years
of age and no further, or less than a 1 cm increase in
linear growth over a minimum of 6 months [5,6].
However, a recent Spanish study on growth including
32 064 normal individuals measured increasing height
up to the age of 24 years, and the median growth
between 18 and 24 years was 1.33 cm in men and 0.01 cm
in women [10], a finding that challenges former
definitions of final height. Thus, we hypothesized that, if
final height is measured during early adulthood,
patients with prepubertal disease onset would be found
to have a smaller adult height than patients with later
disease onset. Thus, the aim of the study was to compare
the final height of IBD patients diagnosed during
childhood with that of patients diagnosed during adult-
hood and to healthy controls. For this purpose, we ana-
lysed data collected in a nationwide multicentre cohort
study on patients with IBD, the Swiss IBD cohort study,
that was initiated in 2006 by the University of
Lausanne [11].
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Patients and methods
As of November, 2012, 2069 patients diagnosed with CD,
ulcerative colitis (UC) or IBD-unclassified (IU) according
to standard criteria [12], included at least 4 months after
diagnosis, were registered in the Swiss IBD cohort study
database. The study protocol for this registry had been
approved by the central and the local ethics committees
in 2006. As described by Pittet et al. [11], patient inclu-
sion was performed by the following six university cen-
tres from western through eastern Switzerland: Geneva,
Lausanne, Bern, Basel, Zurich and St Gallen, with the
University of Lausanne as the coordinating centre and
database location. We retrieved the two types of data
from the registry: (a) information obtained from the
patient chart at the time of enrolment, such as date of
birth, sex, age at inclusion, age at IBD diagnosis, type of
IBD (CD, UC, IU), disease location recorded according
to Montreal classification [13], after verification of a work
up according to inclusion criteria, and the necessity for
surgery, defined as the sum of resectional and minor
perianal surgery, excluding non-IBD-related surgeries,
the cumulative use of corticosteroids and biologic agents,
and (b) measured information, such as height and weight
measured by the study nurse at the visit of enrolment
using the wall stadiometers and weight scales available at
the various study centres. Data of controls were obtained
from the Federal Office of Public Health survey of 2007
[14]. For patients’ inclusion, see the flow diagram shown
in Fig. 1.
Statistics
Continuous data distribution was assessed using Normal-
QQ-plots. Gaussian distributed data were presented as
mean ±SD and range, and non-Gaussian distributed data
were presented as median, interquartile range and range.
Differences in continuous data distribution between two
groups were assessed using Student’s t-test in case of
Gaussian data or using the Wilcoxon–Mann–Whitney
rank sum test in case of non-Gaussian data. Differences
in continuous data distribution between more than two
groups were assessed using Fisher’s F-test in case of
Gaussian data or using the Kruskall–Wallis test in
case of non-Gaussian data. Categorical data were pre-
sented as raw count and relative percentages. Differences
in categorical data distribution between groups were
assessed using the χ2-test or Fisher’s exact test in case of
insufficient sample size. Simple linear regression was
used to assess the effects of several factors on adult
standardized height. Age category for disease onset, dis-
ease location at diagnosis and history of surgery were
used as predictors for each sex and each disease sepa-
rately. For the purpose of this study, a P-value less than
0.05 was considered statistically significant. Bonferroni’s
correction was applied in case of multiple testing.
Results
Male CD patients with prepubertal disease onset had a
significantly lower final height than patients diagnosed at
pubertal or adult age and the male Swiss population. The
diagnosis was made before 1980 in two (final height
170 cm, both), between 1980 and 1989 in six (168,
2× 170, 171, 179, 182 cm) and between 1990 and 1997 in
eight patients (161, 163, 164, 171, 173, 175, 181, 184 cm).
Seven female patients had prepubertal onset of CD
(diagnosis between 1980 and 1989 in four, final height
160× 2, 164, 173 cm, and between 1990 and 1994 in
three, final height 143, 160, 165 cm) and their final height
was not significantly smaller than that of the patients
of any other group. The number of UC/IU patients
with prepubertal disease onset was too small for
analysis. There was no difference for final height in
UC/IU patients with pubertal disease compared with that
of patients with adult-onset disease or the Swiss
population (Table 1). After standardization of the final
Fig. 1
2069 IBD patients
16−88 years old
840 excluded (men
<18, women <22,
all ≥ 44 years) 
675 women 18−44
years old
554 men 22−44
years old
17 847 controls
15−99 years old
10 863 excluded
(men <18, women
<22, all ≥ 44 years)
3913 women
18−44 years old
3071 men 22−44
years old
(a) (b)
Flow diagram of patients included in our study: (a) patients enrolled into the registry of the Swiss IBD Cohort Study, (b) healthy individuals recruited by
the Federal Office of Public Health in 2007 at the time of the public health survey. IBD, inflammatory bowel disease.
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heights of patients against the heights of the coeval Swiss
population, age classes could be compared independent
of sexes, and all patients with prepubertal disease onset
of CD, but not UC/IU had significantly smaller final
heights (Table 2 and Fig. 2) than the other groups.
At disease onset and for both sexes together, ileal disease
location was present in five prepubertal (21.7%), in 31
pubertal (17.5%) and in 116 adult (22.9%), ileocolonic
location was present in 12 prepubertal (52.2%), in 96
pubertal (54.2%) and in 237 adult (46.8%), colonic
Table 1 Final height of patients with IBD grouped according to the age at disease onset
Disease onset Prepubertal (pre)
Pubertal
(pub) Adult (adu)
Healthy
controls (HC)
P-value
overalla Pre vs. pubb
Pre vs.
adub
Pub vs.
adub
Pre vs.
HCb
Pub vs.
HCb
Adu vs.
HCb
Male patients with CD 0.001 <0.001 0.001 0.134 0.001 0.331 0.235
Number of patients 16 90 186 3071
Height (cm) 172 ±6 179 ± 6 178 ±7 178 ± 7
Mean ±SD, range 161–182 161–192 162–200 142–204
Female patients with
CD
0.072 0.065 0.035 0.569 0.172 0.229 0.301
Number of patients 7 87 320 3913
Height (cm) 161 ± 9 165 ±6 166 ±6 166 ± 6
Mean ±SD, range 143–173 151–178 152–183 130–186
Male patients with
UC/IU
0.406 0.741 0.587 0.163 0.778 0.466 0.151
Number of patients 2 68 192 3071
Height (cm) 175 ±13 179 ± 6 178 ±7 178 ± 7
Mean ±SD, range 166–184 164–194 160–197 142–204
Female patients with
UC/IU
0.900 0.740 0.927 0.449 0.466 0.457 0.756
Number of patients 2 27 232 3913
Height (cm) 166 ±1 167 ±6 166 ±6 166 ± 6
Mean ±SD, range 165–166 157–181 150–185 130–186
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC/IU, ulcerative colitis or IBD-unclassified.
aFisher’s F-test.
bStudent’s t-test.
Table 2 Standardized final heights of patients with IBD, normalized against coeval healthy individuals, grouped according to the age group
at disease onset, sex and disease type
Disease onset Prepubertal (pre) Pubertal (pub) Adult (adu)
Healthy
controls (HC)
P-value
overalla Pre vs. pubb
Pre vs.
adub
Pub vs.
adub
Pre vs.
HCb
Pub vs.
HCb
Adu vs.
HCb
Male patients with
CD
0.001 <0.001 0.002 0.111 0.001 0.332 0.189
Number of patients 16 90 186 3071
Standard height −0.8 ± 0.7 0.1 ± 0.7 −0.1 ±0.7 0.0 ±0.8
Mean ±SD, range −2.1–0.4 −2.1–1.5 −2.0–2.3 −3.8–2.7
Female patients with
CD
0.023 0.276 0.199 0.249 0.170 0.061 0.259
Number of patients 7 87 320 3913
Standard height −0.8 ±1.2 −0.2 ±0.8 −0.1 ±0.8 0.0 ±0.8
Mean ±SD, range −3.1–0.9 −2.0–1.4 −2.0–2.0 −4.4–2.5
Male patients with
UC/IU
0.375 0.734 0.804 0.190 0.763 0.542 0.136
Number of patients 2 68 192 3071
Standard height −0.4 ±1.5 0.0 ± 0.7 −0.1 ±0.7 0.0 ±0.8
Mean ±SD, range −1.5–0.7 −1.5–1.8 −2.3–2.0 −3.8–2.7
Female patients with
UC/IU
0.977 0.334 0.406 0.734 0.428 0.795 0.793
Number of patients 2 27 232 3913
Standard height −0.2 ±0.2 0.0 ± 0.8 0.0 ±0.8 0.0 ±0.8
Mean ±SD, range −0.3–0.1 −1.3–1.7 −2.2–2.5 −4.4–2.5
All patients with CD <0.001 0.001 0.001 0.760 0.001 0.480 0.086
Number of patients 23 177 506 6983
Standard height −0.8 ±0.9 −0.1 ±0.8 −0.1 ±0.8 0.0 ±0.8
Mean ±SD, range −3.1–0.9 −2.1–1.5 −2.0–2.3 −4.4–2.7
All patients with
UC/IU
0.515 0.504 0.626 0.245 0.568 0.478 0.258
Number of patients 4 95 424 6983
Standard height −0.3 ±0.9 0.0 ± 0.7 −0.1 ±0.8 0.0 ±0.8
Mean ±SD, range −1.5–0.7 −1.5–1.8 −2.3–2.5 −4.4–2.7
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC/IU, ulcerative colitis or IBD-unclassified.
aFisher’s F-test.
bStudent’s t-test.
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location was present in one prepubertal (4.4%), in 30
pubertal (17.0%), and in 117 adult (23.1%), and unknown
location in 5 (21.7%) prepubertal, in 19 (10.7%) pubertal
and in 31 (6.1%) adult patients. The difference of
unknown locations makes up for the significant differ-
ence between age groups.
Perineal and resectional surgical interventions in patients
with CD of both sexes were required in 18 with pre-
pubertal (78.3%), in 93 with pubertal (52.5%) and in with
193 adult-onset (38.1%) disease (P< 0.05 for each com-
parison), and in 0% with prepubertal, in nine with pub-
ertal (9.5%) and in 21 with adult-onset (5%) disease of
UC/IU (P=NS for each comparison).
Univariate regression analysis enabled exclusion of fac-
tors such as the necessity for surgery or the initial disease
location such as predictors of final height, and age at
diagnosis emerged as the only predictive factor for final
height (Table 3).
Corticosteroid therapy administered before study entry
was recorded in 68% male and 86% female patients with
prepubertal, in 50% male and 47% female patients
with pubertal and in 45.7% male and 44% female
patients with adult onset of CD (P=NS between all groups),
in 48% male and 59% female patients with pubertal and in
33.3% male and 42% female patients with adult onset of UC
or unclassified colitis. Corticosteroid consumption during
growth was not available as cumulative dose per kilo body
weight. Infliximab, authorized for in 1999 for adult and in
2007 for patients 6–17 years of age, was administered in
12.5% male and 0% female patients with prepubertal, in
4.4% male and 16.1% female patients with pubertal and in
9.6% male 10.6% female patients with adult onset of CD, in
9.4% male and 3.7% female with pubertal, in 4.2% male and
2.6% female patients with adult-onset UC/IU.
Discussion
With this study, we could clearly show that final height in
patients diagnosed with CD before the beginning of the
pubertal growth spurt, that is before 13 years in males and
11 years in females, is significantly smaller than that of
patients with later disease onset. Only a few reports have
assessed the final adult height in IBD patients with
paediatric onset disease [4–9]. Prospective studies mostly
included paediatric patients up to the age of 18 years
[4,5], and retrospective studies carried out in adult
patients either analyse patients with CD diagnosed
before the age of 16 or 17 years [7,8] as a single group,
patients with UC and CD as a mixed group [1,9] or report
height measures collected by telephone or from passports
[4]. In this study, we have separately analysed patients
with either UC/IU or CD and with either prepubertal,
pubertal or adult-onset disease, and we have compared
measured and dated final height of patients with pre-
pubertal disease onset with that of patients with pubertal
or adult disease onset and with that of healthy controls.
Our age groups were constituted according to the tables
of Tanner and Whitehouse [15], where the median age at
onset of pubertal growth spurt is 13 years in boys and
11 years in girls, according to data of the Spanish cohort
[10] for the age of achievement of final height and data of
multiple reports [16,17] for the beginning of significant
height loss during adult life. It is noteworthy that the
cutoff of less than 17 years for paediatric age used by
the Montreal classification is based on the need for a
pediatric age group and the cutoff of less than 10 years of
age proposed by the Paris classification on the different
clinical and serologic phenotypes of CD at age before
10 years [18]. None of these classifications are evidence
based for the dynamics of linear growth.
The smaller number of female patients with prepubertal
disease onset in our study most likely reflects the well-
known later onset of CD in females in this age group [19],
and was the reason why a comparison of height was not
possible. However, on comparing pooled standardized
final heights, we could show that all patients with pre-
pubertal onset of CD attained a significantly smaller final
height compared with that of patients with later disease
onset. Furthermore, univariate regression analysis iden-
tified age at diagnosis as the only predictive factor for
adult height of CD patients. No difference in final height
was found in patients with UC, in agreement with the
results of other studies [2].
Corticosteroids were administered in all age groups, with
no statistical difference. Yet, the relevant doses, that is
the cumulative dose administered per kilo body weight
before the beginning of, or during the growth spurt, was
not available for analysis. However, there has always
been a controversy on the impact of corticosteroids on
Fig. 2
4
2
−4
−2
0
S
ta
nd
ar
di
ze
d 
he
ig
ht
CD UC/IU Control
Pubertal
Control
Prepubertal
Adult
Comparison of standardized final heights of patients with CD or UC/IU
and disease onset at prepubertal, pubertal or adult ages. CD, Crohn’s
disease; UC/IU, ulcerative colitis or inflammatory bowel disease-
unclassified.
Final height in paediatric Crohn’s disease Herzog et al. 1237
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
growth dynamics [19,20]. Treatment with biological
agents played no role in the patient groups with pre-
pubertal disease onset of our study as infliximab was
authorized for paediatric patients only in 2007. Initial
disease locations were not found to be different between
age groups of patients with CD and had no impact on
final height. Even though the cumulative lifetime
requirements of perineal and resectional surgery, repre-
senting the severity and behaviour of the disease, were
significantly higher in patients with prepubertal disease
onset, mostly minor perineal surgery, the difference was
not important enough to emerge a predictive factor.
This study has several limitations worth mentioning: first,
our study is not population based. In Switzerland, many
adult IBD patients are followed by gastroenterologists in
private practice, especially patients with uncomplicated
disease living in regions without easy access to university
hospitals. Second, pubertal stages and bone ages of
patients with prepubertal and pubertal diagnosis of IBD
were not available, and some patients categorized as
pubertal may still have been prepubertal, despite their
age. Third, parental heights were not available, but
instead and as useful, we compared patients’ final heights
with population-based height data of coeval healthy
individuals.
In conclusion, by grouping patients according to ages
relevant for growth dynamics, we could show that
patients with CD diagnosed before the onset of growth
spurt achieve a significantly lower final height than
patients with later disease onset, independent of the
initial disease location, need for surgery or corticosteroid
use. Future studies should explore factors delaying or
reducing the pubertal growth spurt in patients with a
prepubertal diagnosis of CD, such as the severity and
the duration of the disease before the beginning of
the growth spurt.
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